Recent assays have evaluated the effect of dupilumab (anti-IL-4Rα) on the host–microbe interface in atopic dermatitis (available online in clinicaltrials.gov, identifier: NCT03389893) [92]. The gene discussed is IL4R; the disease is atopic eczema.